世界杯平台

Home

About us

Management Team

Corporate Culture

Services & Solutions

R&D

Antibody Discovery Developability Assessment

Development

Cell Line

Cell Line Development High-Efficiency Expression Vector

Process Analytical Methods Microbial CGT

Manufacturing

Tech Transfer Drug Substance Drug Product Process Characterization Process Validation

Quality & Support

Quality Control Quality Assurance Regulatory Affairs Project Management IP Management

Animal Health

Case Studies & Experience

Technology Platforms

Cell Line Platform

CHOzen® CHOFlow® GS-KO GlycoExpress® Other Commercial Cell Lines Canvector®

Process Development Platform

CHO-Rise® CBoost™ CanPure™ Purification Platform CanCapture™ Membrane Chromatography Platform CanConcentra™ High-Concentration Formulation Platform

Manufacturing Platform

Scale-Plus Technology Biologics Pulsing Production Line

IgMaxTM

News

Company News

Brochures & Materials

Join Us

Contact Us

Contact Information

Leave a Message

类别产品类型领域

Process

Upstream Process Development

Focus on quality

・Quality by Design
・Risk Management

Competitive development time

・From cell pool to 15L process in 4 months;
・Upstream process lock from a Top 1 cell poolcan be achieved in as fast as 2.5 months;

Unique cell culture platforms

・Orbital shaken cell culture system (10-2500L);
・Stirred-tank Reactor (3L to 2000L);

Advanced upstream cellculture platforms

・Fed-batch culture;
・Intensive fed-batch culture;
・Perfusion culture.

Titer up to ~39 g/L.

Perfusion culture obtains higher
cell fineness and longer culture time.

CBoost™‌

High Inoculation Density and High Expression Levels

Based on optimized inoculation strategies, volumetric productivity is significantly enhanced.

Highly Platformized

Applicable to multiple cell lines and product types, facilitating process transfer and scale-up.

Robust Process with Broad Applicability

The process remains stable across differentscales and culture modes, supporting flexible manufacturing strategies.

CBoost Advanced

Fed-batch Perfusion Culture

High cell viability is maintained through precise nutrient feeding and metabolite control.

Extended Culture Duration

Long-term production is achieved at sustained high cell density, increasing yield per batch.

Maximize Production Efficiency

Comprehensive optimization of process parameters to fully leverage cellular expression potential.

Explore More

Orbital Shaker Bioreactor Platform

Advantages

Shorter mixing time

Lower shear force

Fewer air bubbles

Easy scale-up

Issues in Stirred-TankReactor (STR) Culture

・Low Viability, Low Viable Cell Density
・Protein Aggregation, Low Expression Titer

Switch to OrbitalShaker Bioreactor

・Both cell growth and expression titerhave been improved

CHO-Rise® - Customized Media Development

Next-Generation

Upgraded Formula

30% Enhancement VS Competitors

Serum-Free

Chemically Defined

Perfectly Compatible with Canton's Self-Developed CHOZen® Cells and CANVector® Systems

Excellent Cell Growth and Viability Performance

Powered by Cantonbio CHO-Rise Plus® , CHO-K1 maintains robust growthand near-100 % viability throughout 14-day fed-batch, outperforming commercial alternatives

Cell Growth

High Expression Level, Covering Multiple Modalities

With Cantonbio CHO-RisePlus® medium, mAbs, bsAbs, recombinant and hard-to-express proteins all achieve high titers above industrybenchmarks and competitors.

CHO Rise® Medium demonstrates excellent expression levels across multiple modalities

Explore More

Our Core Competencies

End-to-End Bioprocess Development

Bioprocess development services ready for tech-transfer and scale-up topilot and GMP production

CHO-Rise® Medium development platform

Self developed formula, localized manufacture, significantly reduced costs

Flexible culture platform

Stirred bioreactor, orbital shaken bioreactor

Downstream Process Development

Competitive Development Timeline

Scalable downstream process completed within 2–4 months

Gram‑scale protein for research purposes delivered within 2 weeks

Diversified Chromatography Process Platform

Purification of conventional and special‑configuration antibodies

Tagged / Tag‑free protein purification

Bispecific antibody purification

Advanced Purification Processes

Two‑step antibody purification process

Non‑affinity antibody purification process

High‑throughput membrane chromatography process

Continuous chromatography process

Customized Purification Process Platform

Three‑step IgG platform

Purity > 98%

HCP residual < 20 ppm

Recovery rate ~80%

Two‑step IgG platform

Purity > 98%

HCP
residual < 20ppm

Recovery rate ~ 80%

Non‑affinity IgG platform

Purity > 98%

HCP residual < 50ppm

Recovery rate ~70%

IgG membrane chromatography platform

Purity > 99%

HCP residual < 10ppm

Recovery rate ~70%

IgM platform

Purity > 98%

Host cell protein
residual < 100ppm

Recovery rate ~55%

Bispecific antibody platform

Purity > 97%

HCP residual < 30ppm

Recovery rate ~60%

Recombinant protein platform

Purity > 97%

HCP residual < 50ppm

Recovery rate ~50%

Fusion protein platform

Purity > 97%

HCP residual < 30ppm

Recovery rate ~60%

Formulation and Process Development

Diverse Formulation Dosage Forms

Liquid, lyophilized, semi‑solid, eye drops, inhalation, nasal spray

Experience in Developing Formulations for Various Molecules

Conventional antibodies, special-configuration antibodies, bispecific antibodies, complex recombinant proteins, exosomes

Primary Packaging

Vials, PFS, BFS, nasal spray pumps, inhalation pumps

High‑Throughput Stability Analysis Capability

By measuring Tagg value, stability of 384 samples can be predicted within 1 hour

Formulation development, container‑closure screening,
formulation process development, in‑use stability study

Lyophilized formulaiton

High‑concentration formulation

Liquid injection

Semi‑solid formulation

Inhalation formulation

Nasal spray

Eye drops

Exosomes

Video

Subscribe for Updates